|
|
 |
|
Viewing report
|
|
|
|
Strategic Perspectives 2001: Breast Cancer Cost Analysis
Datamonitor, Feb 2001
Utilizing pricing data amassed from the seven major markets of the US, Japan, Germany, France, Italy, Spain and the UK, this report provides a detailed analysis of the major drug regimes used in the treatment of breast cancer alongside the current pricing and reimbursement status in each of the countries studied. Thus, an intriguing evaluation of the cost of breast cancer treatment is presented. * Plan your investment in pharmacoeconomic studies and patient assistant programs, and intensify links with advocacy groups. * Assess your launch and product lifecycle strategies to remain competitive within the breast cancer market. * Understand how your competitors are differentiating themselves and gaining competitive advantage. * Benchmark your pricing strategies against other breast cancer therapies across the US, Europe, and Japan.
Customers who bought this item also bought
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Breast Cancer Insight - Defining Drug Decisions - How Can Companies Influence the Treatment of Breast Cancer?
Drugs of Tommorow 2002: Breast Cancer
Strategic Perspectives 2002: Colorectal Cancer Cost Analysis
U.S. Breast Cancer Therapeutics Markets
Reimbursement in Europe, Japan and the US: The Impact of Cost Shifting on Pharmaceutical Strategies
Stakeholder Insight: Hormonal Therapies in Breast Cancer
Treatment Algorithms 2001: Lung Cancer
Stakeholder Insight: Adjunct Therapies in Breast Cancer
Br Malls Participacoes Sa
Br. Holdings Corporation
Strategic Perspective 2001: Female Cancers - Optimizing Market Opportunities
|
|
|
|
